000			02142nam a22003137a 4500
003			ZW-GwMSU
005			20201012153942.0
008			201012b ||||| |||| 00| 0 eng d
020			_a9780128022085
040			_bEnglish _cMSU _erda
245			_aDrug discovery in cancer epigenetics _cedited by Gerda Egger and Paola Arimondo
260			_aOxford : _b Elsevier, _c2016
300			_a475 pages : _bill(chiefly color) _c25 cm
336			_2rdacontent _atext
337			_2rdamedia _aunmediated _bn
338			_2rdacarrier _avolume _bnc
490			_aTranslational epigenetics series
504			_aIncludes bibliographical references and index
505			_aI. Introduction. Basic epigenetic mechanisms and phenomena -- Cancer epigenetics -- II. Methods and tools for epigenetic drug development -- Drug discovery methods -- Preclinical cancer models with the potential to predict clinical response -- Discovery of biomarkers for drug development -- Networks and consortia for epigenetic drug discovery -- III. Classes of epigenetic drugs -- DNA methyltransferase inhibitors -- Small molecule inhibitors of histone deacetylases and acetyltransferases as potential therapeutics in oncology -- Targeting histone methylation. The development of selective methyltransferase and demethylase inhibitors -- Bromodomains as anti-cancer targets -- Epigenetic readers interpreting the lysine methylome: biological roles and drug discovery -- Non coding RNAs: clinical and therapeutic applications -- IV. Clinical implications of epigenetic therapy. Clinical applications of epigenetic drugs -- Efficacy of combined epigenetic therapies -- Predicting and monitoring responses to epigenetic drugs -- Episensitization: a new word for a new concept -- The emerging potential for epigenetic therapeutics in non-cancer disorders
650			_aCancer _xGenetic aspects
650			_aEpigenetics
650			_aNeoplasms _xdrug therapy
650			_aGene expression
650			_aDrug development
650			_aNeoplasms _xgenetics
700			_aEgger, Gerda _eeditor
700			_a Arimondo, Paola _eeditor
942			_2lcc _cB
999			_c155319 _d155319